Tanezumab: A Detailed Dive into the 880266-57-9 Reagent Compound
Tanezumab: A Detailed Dive into the 880266-57-9 Reagent Compound
Blog Article
Tanezumab, identified by the research designation 880266-57-9, represents a therapeutic antibody reagent demonstrating significant potential in alleviating severe osteoarthritis pain. This engineered antibody uniquely targets sensory growth element , blocking its effect and thereby lessening discomfort within affected areas . The clinical data surrounding 880266-57-9 highlights its power to offer significant discomfort relief while potentially avoiding the dependence for traditional analgesics. Further studies are currently underway to fully evaluate its sustained safety and effectiveness .
Comprehending Tanezumab's Function in Pain Control: An Body's Defense View
Tanezumab, a groundbreaking therapeutic approach, offers a specific pathway in long-term pain alleviation. As a humanized antibody, it selectively targets and blocks nerve growth factor (NGF), a critical molecule involved in nerve ache signaling. Unlike conventional opioid medications, tanezumab’s immune mechanism allows for a greater specific action, possibly decreasing the chance of some frequent side effects associated with systemic pain alleviation. However, its body's defense nature necessitates a here thorough consideration of possible allergic reactions and extended impacts when employed within a complete pain management plan.
Tanezumab Compound (880266-57-9): Quality , Purity & Uses
The Tanezumab Compound with the identifier 880266-57-9 is a critical component in various biomedical applications, particularly concerning joint pain treatment development. Achieving a high level of quality is paramount; therefore, rigorous testing protocols are employed to guarantee its fitness for specific use. Our manufacturing process focuses on prioritizing purity , employing sophisticated filtration techniques to remove impurities . Typical characteristics include a >95% purity level as determined by Liquid Chromatography and comprehensive testing for protein integrity. The primary functions revolve around its role as a scientific resource for investigating pathways of arthritis progression and innovative therapeutic interventions .
- Research Investigations
- Drug Development
- Mechanism Studies
The Investigation Behind Tanezumab:
Tanezumab, identified by the chemical identifier 880266-57-9, represents a innovative biological immunoglobulin targeting pain-sensing development substance receptor (NGF). This mode of action revolves upon precisely connecting to NGF, consequently blocking its function and subsequent communication propagation. Scientists have demonstrated that this biologic compound offers promise for managing chronic suffering, particularly associated with illnesses like arthritic conditions and peripheral back discomfort. Additional studies are underway to thoroughly characterize its effectiveness and security characteristics.
Recent Advances in The Research: Examining the 880266-57-9 Substance
Current analyses surrounding tanezumab, a novel therapeutic agent, are increasingly directed on understanding the role of the identified reagent, 880266-57-9. The detection and detailed assessment of the molecular entity seems necessary for enhancing the drug's efficacy and minimizing anticipated adverse outcomes. Initial data reveal that the reagent functions a important role in the therapy's mechanism of delivery. More exploration will be essential to completely understand the reagent’s effect.
Tanezumab Antibody (880266-57-9): Production, Characteristics, and Potential
The production process of tanezumab, an humanized monoclonal antibody (identified by CAS number 880266-57-9), typically involves mammalian cell culture, often utilizing Chinese hamster ovary cells for high yield. Its primary characteristic is its ability to selectively target and degrade cathepsin-K, an enzyme crucial for bone resorption. This binding mechanism results in a significant reduction in osteoclast activity. The molecule exhibits a defined molecular weight and specific amino acid sequence, allowing for detailed characterization through techniques such as mass spectrometry and protein sequencing. Consequently, tanezumab’s potential lies in treating conditions characterized by excessive bone loss, like osteoarthritis and metastatic bone disease, although clinical development has been complex due to adverse event profiles and ongoing evaluation.}
Report this page